Neurocrine Biosciences (NBIX) Soars 3.71% on UBS Price Target Hike

Neurocrine Biosciences (NBIX) shares surged 3.71% today, marking the second consecutive day of gains, with a total increase of 4.40% over the past two days. The stock price reached its highest level since February 2025, with an intraday gain of 3.84%.

UBS has raised its price target for Neurocrine Biosciences from $152 to $174 while maintaining a "Buy" rating. This update, dated July 2, 2025, reflects positive expectations for the company's stock performance and has significantly influenced the current perception of Neurocrine Biosciences' stock. The revised price target suggests that UBS analysts are optimistic about the company's future prospects, which has likely contributed to the recent upward trend in the stock price. Investors are closely watching Neurocrine Biosciences as it continues to demonstrate strong performance and potential for growth.